Weekly Roundup for JUNE 3, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Zuranolone for Postpartum Depression: Results from the SKYLARK Study
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment.
How to Talk to Children About the Texas Shooting
There is no easy way to talk to children about the tragic events in Uvalde Texas. Here are some resources for parents and caregivers.
Pregnant Women with Depression: Greater Use of Cannabis and Benzodiazepines, But Not Antidepressants
Cannabis use, as well as use of benzodiazepines and sedative-hypnotic medications, was more common in women with depression.
More Data on Second Generation Antipsychotic Medications and Gestational Diabetes
Second-generation antipsychotic medications associated with high metabolic risk (quetiapine, olanzapine, and clozapine) were associated with increased risk of gestational diabetes; other antipsychotics were not.
Essential Reads: Neurodevelopmental Outcomes in Children with Prenatal Exposure to Benzodiazepines and Z-Drugs
Our data regarding prenatal exposure to BZDs and/or z-drugs and risk of neurodevelopmental outcomes is still sparse.